Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy.
The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to reflect the therapy’s overall benefits beyond spasticity itself.
Future controlled studies are needed to confirm these potential benefits in patients considered to be unresponsive to Sativex, based on changes in a spasticity scale.
The study, “Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study,” was published in the journal Neurological Sciences.
Spasticity is a common MS symptom, causing muscles to feel stiff and heavy, and making movement difficult. In MS, spasticity is directly or indirectly associated, in varying severity, with a number of other symptoms, including cramps and nocturnal spasms, jerking movements, pain, bladder problems, and/or sleep disorders.
Studies suggest that the severity of spasticity directly correlates with MS patients’ well-being and overall quality of life. Despite the existence of first-line anti-spastic medications, some MS patients are resistant to them.
Sativex, developed and commercialized by GW Pharmaceuticals, is approved in the European Union and other regions as an add-on therapy for adult MS patients with moderate-to-severe spasticity resistant to first-line anti-spastic treatments.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?